Clinical Trials Logo

Signs and Symptoms, Digestive clinical trials

View clinical trials related to Signs and Symptoms, Digestive.

Filter by:
  • Completed  
  • Page 1 ·  Next »

NCT ID: NCT05603403 Completed - Clinical trials for Signs and Symptoms, Digestive

Efficacy And Safety Of Probiatop In The Treatment Of Digestive Symptoms

Probiatop
Start date: October 20, 2022
Phase: Phase 4
Study type: Interventional

A Multicenter, Randomized, Double-blind, Placebo-Controlled Clinical Trial to Evaluate the Efficacy and Safety of Probiatop in the Treatment of Digestive Symptoms. Phase IV. The casuistic presented in this protocol is 150 participants randomized at a 1:1 ratio (75 receiving Probiatop and 75 receiving placebo), balanced by age, sex, prebiotic intake* and summation of the Gastrointestinal Symptom Rating Scale (GSRS) questions related to the domains of diarrhea (questions 11, 12, and 14), indigestion (questions 6, 7, 8, and 9), and constipation (questions 10, 13, and 15) separated by intensity and frequency. Participants with recurrent digestive symptoms for at least 3 months, with a score of 21 on the sum of questions 6, 7, 8, 9, 10, 11, 12, 13, 14 and 15 of the GSRS (corresponding to the domains diarrhea, indigestion and constipation) will be randomized to Probiatop or placebo.

NCT ID: NCT04534036 Completed - Constipation Clinical Trials

Tolerability and Functional Assessment of a Novel Children's Synbiotic

PDS-08™
Start date: August 13, 2020
Phase: N/A
Study type: Interventional

Recent data support the use of specific probiotic strains in a pediatric population. However, given the wide number of commercial products available, and contradictory data in the literature, healthcare providers and consumers are uncertain about whether or not to use probiotics in children and which one(s) to choose. While much progress has been made in understanding the gastrointestinal microbiota and its role in the balanced development of the infant immune system, the tolerability and efficacy of introducing beneficial microbes into the pediatric gastrointestinal tract remain underexplored. The purpose of this study is to investigate the effect of a 9 strain synbiotic consortium comprised of strains with previous pediatric clinical data for use in modulating airway sensitivity, gastrointestinal discomfort, dermatological inflammation, and reduction in the duration and severity of upper respiratory tract infections in a pediatric population.

NCT ID: NCT04273659 Completed - Clinical trials for Unidentified Gastrointestinal Symptoms Following Pulses Consumption

Combining Cereals With Pulses - Reduced Gastrointestinal Symptoms?

Start date: February 12, 2020
Phase: N/A
Study type: Interventional

The aim of the study is to compare self-reported gastrointestinal symptoms and intestinal fermentation rates of the study products as measured by breath hydrogen and methane in adult population with self-reported mild abdominal sensitivity to pulses. The study products are a pulse products with two different cereals.

NCT ID: NCT02677090 Completed - Clinical trials for Signs and Symptoms, Digestive

Fiber Tolerability in Children Aged 3-7 Year

Fiber - TIC
Start date: January 2016
Phase: N/A
Study type: Interventional

Determination of the digestive tolerability of the PROMITOR® in children from 3 to 7 years old.

NCT ID: NCT02532985 Completed - Clinical trials for Signs and Symptoms, Digestive

Gastrointestinal Tolerability Following Multiple Servings of a Novel Dietary Fiber

Start date: October 2014
Phase: N/A
Study type: Interventional

The study will assess the gastrointestinal tolerability of multiple servings of a novel dietary fiber at three different dose levels in generally healthy men and women. Double-blind controlled, cross-over clinical trial with negative (no added fiber) and positive controls. Multiple servings over 24h, with data collection at 24 and 48h and 1 week wash-out between cross-overs. 45 randomized, generally healthy men and women, 18-54 y, BMI higher or equal to 18.5 and smaller or equal to 39.99 kg/m2. Novel dietary fiber ingredient and positive control will be delivered in 240 ml beverages.

NCT ID: NCT02530762 Completed - Clinical trials for Signs and Symptoms, Digestive

Acute Gastrointestinal Tolerability Following a Single Serving of a Novel Dietary Fiber

Start date: September 2014
Phase: N/A
Study type: Interventional

The study will assess the gastrointestinal tolerability of a single serving of a novel dietary fiber at three different dose levels in generally healthy men and women. Double-blind controlled, cross-over clinical trial with negative (no added fiber) and positive controls. Single dose, with 24 hours data collection and 1 week wash-out between cross-overs. 45 randomized, generally healthy men and women, 18-54 y, BMI higher or equal to 18.5 and smaller or equal to 39.99 kg/m2. Novel dietary fiber ingredient and positive control will be delivered in 240 ml beverages.

NCT ID: NCT02519374 Completed - Clinical trials for Signs and Symptoms, Digestive

Fiber Tolerability in Children

FITIC
Start date: June 2015
Phase: N/A
Study type: Interventional

Assessment of the digestive tolerability of the PROMITOR® .

NCT ID: NCT02253628 Completed - Stress Clinical Trials

The Acute Effect of Coffee Consumption on Stomach, Self-reported Gastrointestinal Symptoms and Stress.

Start date: February 2014
Phase: N/A
Study type: Interventional

This study investigated the acute effect of the consumption of four different kinds of coffee (hot and cold instant coffee, cold espresso and hot filter coffee) with the same caffeine content on salivary gastrin, cortisol and alpha-amylase concentrations, on self-reported gastrointestinal symptoms and on psychometric assessments in healthy individuals.

NCT ID: NCT02180035 Completed - HIV Clinical Trials

Treatment With Nutritional Eating Plan and Dietary Fibers in Adult Patients With HIV/AIDS

PRECOR-NUT
Start date: October 2009
Phase: N/A
Study type: Interventional

To evaluate if nutritional treatment with nutritional supplementation of dietary fiber reduces cholesterol levels and triglycerides (dyslipidemia) in patients with HIV/AIDS receiving antiretroviral therapy (HAART).

NCT ID: NCT02099591 Completed - Clinical trials for Constipation, Signs and Symptoms, Digestive

Phase I Pharmacokinetics and Safety Study of Naloxegol in Paediatric OIC Patients

Start date: November 2014
Phase: Phase 1
Study type: Interventional

To characterize the pharmacokinetics (PK) of naloxegol after single oral dose and through population PK in paediatric patients with opioid induced constipation (OIC) or at risk of OIC.